Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2013 | 12-2012 | 09-2012 | 06-2012 | 12-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,228 | -20,100 | -14,789 | -10,144 | -23,700 |
| Depreciation Amortization | 344 | 1,460 | 1,088 | 704 | 1,190 |
| Income taxes - deferred | N/A | N/A | 4,789 | 3,317 | N/A |
| Accounts payable and accrued liabilities | 829 | N/A | -581 | -869 | N/A |
| Other Working Capital | -5,521 | -38,370 | -29,366 | -20,586 | 17,580 |
| Other Operating Activity | -405 | 7,470 | 940 | 1,058 | -10,280 |
| Operating Cash Flow | $-11,981 | $-49,540 | $-37,919 | $-26,520 | $-15,210 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -275 | -1,470 | -1,449 | -308 | -1,900 |
| Purchase Of Investment | -15,915 | N/A | -71,110 | -50,649 | N/A |
| Sale Of Investment | 20,226 | N/A | 75,764 | 55,884 | N/A |
| Other Investing Activity | 0 | 24,510 | 0 | 0 | -20,460 |
| Investing Cash Flow | $4,036 | $23,040 | $3,205 | $4,927 | $-22,360 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 25 | N/A | 88 | 54 | N/A |
| Other Financing Activity | 0 | 140 | 0 | 0 | 77,350 |
| Financing Cash Flow | $25 | $140 | $88 | $54 | $77,350 |
| Beginning Cash Position | 91,297 | 117,660 | 117,661 | 117,661 | 77,880 |
| End Cash Position | 83,377 | 91,290 | 83,035 | 96,122 | 117,660 |
| Net Cash Flow | $-7,920 | $-26,360 | $-34,626 | $-21,539 | $39,770 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,981 | -49,540 | -37,919 | -26,520 | -15,210 |
| Capital Expenditure | -275 | N/A | -1,449 | -308 | N/A |
| Free Cash Flow | -12,256 | -49,540 | -39,368 | -26,828 | -15,210 |